info@upjac.com  | +1 (347) 486-4833

United Journals and Conferences

Our Most Valuable Keynote Speakers

United Conference of Nanotechnology and Medicine

Soshu Kirihara

Professor of Joining and Welding Research Institute (JWRI), Osaka University, Japan

Yasin Oduk
Yasin Oduk

Chief Executive Officer at NanomediGene LLC, United States

Mallesh Kurakula
Mallesh Kurakula

Formulation Scientist, United States

Alexander Seifalian
Alexander Seifalian

Director/Professor of Nanotechnology & Regenerative Medicine & NanoRegMed Ltd, United Kingdom

Brandon Ortiz Casas

Investigator & Quality Manager, Nanopharmacia Diagnóstica, Mexico

Roberto Vazquez-Munoz
Roberto Vazquez-Munoz

Nanomedicine Scientist, USA

Dr. Alain L. Fymat

Founding Chair, President/CEO and Institute Professor at International Institute of Medicine & Science

United Conference of Pharmacovigilance

Gareme Ladds
Graeme Ladds

CEO PharSafer Associates Ltd - Global Leaders in Drug Safety, United Kingdom

Nashwa Nashaat

CEO & Co-Founder Nexus eHealth Formal regional Medical Director for J&J and Eli Lilly Novartis: Pharmacovigilance Lead

Liana Kasyan
Liana Kasyan

Founder/CEO and Principal PV Consultant at ETL Pharmacovigilance Center Ltd. Armenia

Julia Appelskog

EU QPPV, Head of QPPVs & Safety Consulting. Pharmacovigilance Director, Sweden

Penelope Przekop

Chief Compliance Officer at Engrail Therapeutics | CEO at PDC Pharma Strategy, USA

Dr. Dina Avery

Assistant Professor & Associate Scientist - University of Alabama at Birmingham, USA

Asif Mahmood
Asif Mahmood

Chief Safety Officer/Vice President Global Safety & Pharmacovigilance, Medicago, Canada

Shereen Agwa
Shereen Agwa

Country Safety Team Lead for South Africa and Sub Saharan Africa, Egypt

Sunil Verma
Sunil Verma

DIRECTOR – PHARMACOVIGLANCE, HAROM Solutions, India

Dr. Preeti Patel
Dr. Preeti Patel

Drug Safety Associate, Sollers, United States

Ilana Frishman
Ilana Frishman

Safety Director at Pluristem Therapeutics, Israel

Snezana Stankovic
Snezana Stankovic

Pharmacovigilance Manager at FDA

Hadir Rostom

President - International Society of Pharmacovigilance (ISoP)- Egypt Chapter & Pharmacovigilance Expert Consultant, Egypt

United Conference of Drug Development and Industrial Pharmacy

Danielle Drachmann

Executive Director at Ketotic Hypoglycemia International, Committee member at the European Health Parliament, Patient Representative at the European Medicines Agency, Rare2030 EURORDIS, Europe

Marieke Meulemans
Marieke Meulemans

CEO GCP Central B.V.,Amsterdam, North Holland, Netherlands

Hayley Lewis

Senior Vice President, Operations at Zosano Pharma, California, USA

Dr. Nalini kanta Sahoo

Principal, SRM Modinagar college of Pharmacy, Delhi-NCR campus, India

Qihan Dong MD, PhD

Director, Chinese Medicine Anti-cancer Evaluation Program, Sydney Medical School The Faculty of Medicine and Health, The University of Sydney, Australia

Li, Fengzhi
Li, Fengzhi

Faculty member at Roswell Park Comprehensive Cancer Center, Roswell Park Cancer Institute, USA

Jim Hauske

President and founder at Sensor Pharma, United States

Anup Madan

Director, Biomarkers at PPD, USA

James T. O'Donnell
James T. O'Donnell

Pharmacologist Drug Expert, Associate Professor at Rush Medical College, United States

United Conference of Quality and Validation

Dishant Sanghavi

Senior Manager - Global Quality and Compliance, Sun Pharma, India

Hashim Ahmed
Hashim Ahmed, Ph.D., WHO Fellow

Sr. Director-Head of Formulation and Manufacturing, Avomeen, United States

Penelope Przekop

Chief Compliance Officer at Engrail Therapeutics | CEO at PDC Pharma Strategy, United States

Ravi Kalyanaraman
Ravi Kalyanaraman, Ph.D.

Director, Global Analytical Science & Technology - Pharma & Forensics Bristol Myers Squibb, United States

Timur Güvercinci
Timur Güvercinci

Director, Head of External Supply Quality Processes and Development bei Merck Gruppe Global Quality, Germany

Gloria Carmona
Gloria Carmona

Head of Quality Assessment and GMP Facilities. Andalusian Network for the design and translation of Advanced Therapies (ANd&tAT). Fundación Pública Andaluza Progreso y Salud.

Stephan O. Krause
Stephan O. Krause

Head of Product Quality Group at AstraZeneca Biologics, USA

Dhaval Surti
Dhaval Surti

AGM, QA with Emcure Pharmaceutical Ltd, Ahmedabad, Gujarat, India

Kumar Ashesh
Kumar Ashesh

CEO at Paras Biopharmaceuticals Finland Oy Oulu, North Ostrobothnia, Finland

Elie Arslan
Elie Arslan

Manager, Technical QA and Document Control at Ajinomoto Bio-Pharma, California, United States

Rohit Sompura
Rohit Sompura

DGM QA at Sterile dosage plant of Alembic Pharmaceuticals Limited

Akihiko Hanafusa

Professor, Shibaura Institute of Technology, Japan

United Conference of Generic Medicine, Vaccines and Biosimilars

Timur Güvercinci
Timur Güvercinci

Director, Head of External Supply Quality Processes and Development bei Merck Gruppe Global Quality, Germany

Hashim Ahmed
Hashim Ahmed, Ph.D., WHO Fellow

Sr. Director-Head of Formulation and Manufacturing, Avomeen, United States

Penelope Przekop

Chief Compliance Officer at Engrail Therapeutics | CEO at PDC Pharma Strategy, United States

Ravi Kalyanaraman
Ravi Kalyanaraman, Ph.D.

Director, Global Analytical Science & Technology - Pharma & Forensics Bristol Myers Squibb, United States

United Conference of Digital Transformation of Pharmaceutical Industry

Nashwa Nashaat

CEO & Co-Founder Nexus eHealth Formal regional Medical Director for J&J and Eli Lilly Novartis: Pharmacovigilance Lead

Manish Saxena

Senior Vice President - Digital Transformation Projects, Tech Mahindra, USA

Alessandro Ferri

Managing Director - Advice Pharma Group S.R.L., Co-Owner - Alfa Technologies International, Co-Founder - daVinci Digital Therapeutics, Italy

Philippe GERWILL

Executive Consultant at Fusion Consulting

Dr Modather Marzouk

Medical Doctor (GP) & Africa Advisor for Digital Health Transformation, General Practitioner, Cabinet Medical, Tunisia

Ahmed Nouh
Ahmed Nouh

Director, Digital Healthcare Business Unit at Vodafone Egypt

Dr. Monika Sonu
Dr. Monika Sonu

CEO & Director New Product Development, Healthinnovationtoolbox, India

Vincent Galand
Vincent Galand

Founding Partner, Digital Pharma Lab & Head Of Partnerships, Health Innovation Coalition, France

Steve Peretz
Steve Peretz

Director, Health Experience & Product Strategy, Appnovation, United States

Kurtulus Gokduman
Kurtulus Gokduman

Founder – BIOMEDRIC & Visiting Scientist, Harvard Medical School and Massachusetts General Hospital, United States

Inderpreet Singh Kambo
Inderpreet Singh Kambo

Client Partner - Axtria - Ingenious Insights, United States

Mekala.S.Rao
Mekala.S.Rao

Digital Transformation leader, Founder of Atachi Systems

United Conference of Biometrics and Data Management

Ena Bromley
Ena Bromley

CEO at Analytika, Inc. United States

Carl DiCasoli
Carl DiCasoli

Director Biostatistics at Sumitomo Dainippon Pharma America, Inc. USA

Matthew Giarmo
Matthew Giarmo

Senior Data and Management Analyst, Washington DC-Baltimore Area

Howard Urnovitz

CEO FBB Biomed, United States

Lixia Wang

Vice President, Intercept Pharmaceutical, California, United States

Arkady Gershteyn
Arkady Gershteyn

Principal Biostatistician at PRA Health Sciences, Greater Boston, USA

Avik Pal
Avik Pal

Founder & CEO, CliniOps, Fremont, California, United States

United Conference of Clinical Trials and Clinical Research

Mahendra Singh (WHO)

Founder & CEO | Chief R&D & AI Health Innovation Officer| Chief Digital Health Officer & Chief Strategy Officer @Global DigiAIHealth | Expert Member for Digital Health, AI Health, WHO Geneva.

Marieke Meulemans
Marieke Meulemans

CEO GCP Central B.V., Amsterdam, North Holland, Netherlands

Nashwa Nashaat

CEO & Co-Founder Nexus eHealth Formal regional Medical Director for J&J and Eli Lilly Novartis: Pharmacovigilance Lead

Karmen Trzupek
Karmen Trzupek

Director, Clinical Trial Services at InformedDNA, United States

Ted Barduson
Ted Barduson

COO, Co-Founder at MedVector Clinical Trials

Alekhya Pochiraju

Clinical Operations | Genentech,, United States

Ted Barduson
Ted Barduson

COO, Co-Founder at MedVector Clinical Trials

Michael Sassano
Michael Sassano

Founder, Chairman & CEO Somai Pharmaceuticals; Leading Mergers as Founder of Solaris Farms; Investor, Cannabis, GMP Specialist, Alternative Medicine

United Conference of COVID-19 Pandemic

Richard B.M. Schasfoort
Richard B.M. Schasfoort

Founder of IBIS Technologies BV

Robert Conradt
Robert Conradt

CONRADT Measurement and Control Technology, Germany

Gail Trauco
Gail Trauco

Advisory Committee Member COVID-19 FDA, Principal CEO The PharmaKon LLC, USA

Ahmed A Bashir
Ahmed A Bashir

GCSRT, Harvard Medical School, USA

Gustavo G. Cortina Rodríguez
Gustavo G. Cortina Rodríguez

Director of Quality of Life Office University of Puerto Rico- Mayaguez Campus

Gerard Charles
Gerard Charles

PhD Gerontology (Candidate), Singapore University of Social Sciences & Singapore General Hospital, Department of Emergency Medicine, Singapore

Irina Zyrianova
Irina Zyrianova

Institute for Innovative Biotechnologies in Animal Husbandry, the branch of L.K. Ernst Federal Science Center for Animal Husbandry, Russia

Sandro Serpa
Prof. Dr Sandro Serpa

University of the Azores

United Conference of Women Leaders in Pharma

Huma Qamar
Huma Qamar MD, MPH

Senior Vice President, Head of R&D Program, FSD Pharma, Inc. USA

Hetal Shah
Dr Hetal Shah

Pharmaceuticals & CROs - Independent Consultant & Founder-Director - MeWriT Healthcare Consulting, India

Gail Trauco
Gail Trauco

Advisory Committee Member COVID-19 FDA, Principal CEO The PharmaKon LLC, USA

Dr Lia Hunter
Dr Lia Hunter

Director Clinnovate Ltd, south Croydon, England, United Kingdom

Galyna Malygina
Galyna Malygina

Senior Project Manager, LLC OtiPharm® Data Pro

Rebecca Centko
Rebecca Centko

Director of Project Management & Account Management, Regis Technologies, USA

United Conference of B2B

Mark Nuijten
Mark Nuijten

A2M, member of the MINERVA Health Economics Network, Ltd

brahim Ghareeb Madian Mohammed
Ibrahim Ghareeb Madian Mohammed

GMP executive Consultant

A. C. Matin
A. C. Matin, Ph. D.

Professor of Microbiology & Immunology, Stanford University School of Medicine, USA

Ying-Xian Pan, MD/PhD

Professor Department of Anesthesiology, Rutgers New Jersey Medical School, USA

Shreya Badhrinarayanan, MD

Medical Director | Clinical Development

Dr. Gheorghe FUNDUEANU
Dr. Gheorghe FUNDUEANU

Petru Poni” Institute of Macromolecular Chemistry-Iasi-Romania, Department of Natural Polymers, Bioactive and Biocompatible Materials, Romania.

Vuong Trieu
Vuong Trieu

Chairman & CEO at Oncotelic Therapeutics, USA

Biography: Graeme Ladds has worked in Global Pharmacovigilance and Medical Affairs for the last 30 years working with many top ten Pharma in senior positions. He has worked in all areas of Pharmacovigilance and has designed and improved many IT solutions to aid both Medical Affairs and Pharmacovigilance. Graeme is also an experienced GCP/PV auditor having audited many Companies globally as well as helping Companies in Regulatory Inspections. He now works in his CRO - PharSafer Associates Ltd
Nashwa Nashaat
CEO & Co-Founder Nexus eHealth Formal regional Medical Director for J&J and Eli Lilly Novartis: Pharmacovigilance Lead
Biography: She has dedicated her career to improving the patients’ care and healthcare services. Inspired by the advancement in technology and her personal mission to serve patients, she has co-founded a company where the unmet patient’s needs drive the innovation for personalized technology-based solutions. In her role as a Chief Executive Officer and Co-founder for Nexus eHealth, she is committed to being a catalyst in the adoption of precision medicine through the Technology Enabled Connected Care solutions and building the healthcare technology capabilities, especially in the Middle East and Africa.
Prior to founding Nexus eHealth, being a physician; with PhD in Pediatric Oncology/Hematology, she devoted her passion to improve cancer patients’ lives and affordability of medicine by working with different global medical societies, NGOs and policy makers for more than 18 years. She has also worked for top multinational pharmaceutical, diagnostics and medical devices companies (Novartis, Eli Lilly and Johnson & Johnson) during the last 11 years where she took several global executive leadership roles in R&D, GxP auditing, medical affairs, patients advocacy and support programs, governmental affairs, business development, market access, healthcare policies and digital transformation strategies.

She was honored with 25 global awards for innovation, excellence and patient centricity. She authored more than 20 scientific publications. She serves as technical advisor and organizational leadership coach qualified by Glasgow university. She has been volunteering in different community services in Africa and a member in the Global Camper of Commerce and Industry (GCCI) that support the spirit of entrepreneurship. She is an Egyptian woman who constantly advocates the promotion of equality, diversity and inclusion & woman empowerment across the corporate world and the society as a whole.
Liana Kasyan
Liana Kasyan
Founder/CEO and Principal PV Consultant at ETL Pharmacovigilance Center Ltd. Armenia
Biography: Founder/CEO and Principal PV Consultant at the ETL Pharmacovigilance Center Ltd., - Pharmacovigilance Instructor at the Open Education Office of the American University of Armenia, - Member of International Society of Pharmacovigilance (ISoP), - International Editorial Board Member for the Journal of Pharmacovigilance and Drug Research (JPADR), - Reviewer of Master Тheses at the Faculty of Public Health of Yerevan State Medical University, - Board Member of Armenian Association of Specialists in Evidence-Based Medicine (AASEBM), - Co-founder of “Do not Harm’’ Health NGO.
Biography: Executive director at Ketotic Hypoglycemia International. Her work started with the establishment of an international patient association where they are in close collaboration with national and international researchers, have written scientific papers and conducted research projects using a Citizen Science approach. Most recently, she entered the European Health Parliament and the European Medicines Agency as a Patient Representative for patients with rare hypoglycemia diseases. Furthermore, she have been working for EURORDIS (European Organization for Rare Diseases) to develop recommendations for Europes' rare disease policy in the Rare2030 project.
Marieke Meulemans
Marieke Meulemans
CEO GCP Central B.V., Amsterdam, North Holland, Netherlands
Biography: She is a Founder and CEO of GCP Central since 2012 with over 15 years of experience within the clinical research world, and is the driving force behind the company vision.

Expertise:
•Development of practice-based and effective online GCP training for clinical research professionals.
•Setup and implementation of Learning Management Systems.

Specialties: eLearning development ; online GCP training; training needs analysis; process improvement; training management; blended learning; Good Clinical Practice; Clinical research rules & regulations; Wet Medisch Wetenschappelijk Onderzoek (WMO) training
Hayley Lewis
Senior Vice President, Operations at Zosano Pharma, San Francisco Bay Area, California
Biography: Hayley Lewis serves as our Senior Vice President of Operations, where she oversees the functional areas of Nonclinical, R&D, Analytical Development and QC, Operations and Engineering, Manufacturing, and Regulatory Affairs, and continues to be responsible for overseeing all regulatory interactions with the FDA and other government agencies. Hayley joined the company as the Vice President of Regulatory Affairs and Quality in October 2015.
Prior to joining Zosano, Hayley spent over 11 years in Regulatory Affairs at Depomed, Inc., a specialty pharmaceutical company, where she was involved in the approval of 3 commercial products. Over the course of her career, she has enabled 8 investigational products to be studied in humans, 5 of which have advanced to completion of Phase 3 trials. Hayley’s pharmaceutical development experience, spanning over 20 years, covers solid oral dosage forms, and combination products such as systemic and local inhalation products, a single entity combination injectable, and transdermal systems. Ms. Lewis received a B.S. in Pharmaceutical Sciences from the University of Greenwich in England, and has attained several management diplomas from Kellogg School of Management, as well as Stanford’s Graduate School of Business.
Biography: Fengzhi Li became a faculty member at Roswell Park Comprehensive Cancer Center (legal name: Roswell Park Cancer Institute, the first cancer institution in the US history and is a US NCI-designated comprehensive cancer center) in 2001 after finishing his postdoctoral training in Dr. Dario C. Altieri’s laboratory at Boyer Center for Molecular Medicine, Yale Medical School where he focused his research on the characterization of the function and expression regulation of a newly discovered antiapoptotic protein named survivin (a novel member of the inhibitor of apoptosis protein family). In 2006 he has been promoted to Associate Professor of Oncology at Roswell Park. As a chief scientist, he leads his lab using the survivin gene as a target and biomarker for targeted drug discovery. He has transitioned his Roswell Park cancer research lab from basic to translational cancer research over the past decade. His current research interests focus on targeted anticancer drug discovery, development and mechanism of action (MOA) studies. His research has been supported through federal agencies (NIH/NCI, DOD) as well as other public/private foundations and partnerships. He has published over 80 publications (h-index, 47 and i10-index, 73) with a total citation of over 13,000 times. He is the editorial board members in several academic journals including J Exp Clin Can Res (2019 IF: 7.068), Am J Transl Res (2019 IF: 3.375) and Int J Mol Sci (2019 IF: 4.556). He is also the Chief Scientific Officer (CSO) of Canget BioTekpharma LLC (www.canget-biotek.com) and helps Canget to develop innovative targeted anticancer drugs (high efficacy with low toxicity) for benefiting cancer patients.
Anup Madan
Director, Biomarkers at PPD
Greater Seattle Area, Washington, USA.
Biography: Highly-motivated and proactive leader with a passion to collaborate effectively with all necessary team members, both internal and externally, for delivering life-changing therapies to patients. Extensive expertise in translational oncology, biomarker research and business administration. Strong knowledge in computational biology, and data mining, experienced in pre-clinical and clinical genomics. Creative thinker and problem solver; rapidly adapts to new projects and a changing work environment. Highly productive in matrix organizations or independent working environments. Strong ability to work cross functionally to define and implement strategies that impact decision making. Possesses excellent communication, and presentation skills.
Hashim Ahmed
Hashim Ahmed
Head of Formulation and Manufacturing at Avomeen. Wake Forest, North Carolina, United States
Biography: A pharmaceutical product development executive leader with wide experience in CMC/MS&T-product development-R&D expertise with in-depth diversified global technical and management experience. Expert in formulation/process/product development supply management; and quality assurance of pharmaceutical/consumer products. Over 26 years of experience in the United States in major, medium-to-small companies (Roche/Stiefel-GSK/Dr. Reddy's). Consumer Product Development and regulatory expert in a diverse portfolio of APIs and a wide range of dosage forms, with NDA/505b2/generic-ANDA experience.
In-depth experience in small and large molecules (proteins/peptides); orals (tablets, capsules [hard-soft gel]); controlled-modified release formulations; as well as/parenterals dosages. Expert in oral Liquids Emulsions-Suspensions, Lipids, Powders, Topicals, Transdermals, Ocular delivery, Intranasal, Aerosols. SKILLS: Proven Product Development/CMC/Regulatory Leader (26 years in the USA at different pharmaceutical technical and management capacities); currently managing general director at QLife the lead pharma company in Qatar.
Penelope Przekop
Chief Compliance Officer at Engrail Therapeutics | CEO at PDC Pharma Strategy
Biography: Penelope Przekop, MSQA, RQAP-GCP is the CEO of PDC Pharma Strategy, a consulting firm that focuses on strategic GxP regulatory and corporate compliance. She currently dedicates half of her time to serving as Chief Compliance Officer for Engrail Therapeutics, Inc. She has 30-plus years of broad and deep pharma industry experience and is known for her creative approaches to developing efficient quality management strategies that enable companies of all sizes to build upon their unique drug development history and strengths while ensuring compliance.
Penelope earned her B.S. in Biology from Louisiana State University and her M.S in Quality Systems Engineering from the Kennesaw State University. She is a frequent industry speaker and writer. She is the author of Six Sigma for Business Excellence (McGraw-Hill). Her upcoming book, 5-Star Career (Productivity Press, fall 2021), will relay how readers can apply the proven science of quality management to career development.
Gloria Carmona
Gloria Carmona
Head of Quality Assessment and GMP Facilities. Andalusian Network for the design and translation of Advanced Therapies (ANd&tAT). Fundación Pública Andaluza Progreso y Salud.
Biography: Gloria Carmona is Head of Quality Assessment and GMP facilities in the Andalusian Network for the Design and Translation of Advanced Therapies (former Andalusian Initiative for Advanced Therapies), organization in which she has been working since 2008. She coordinates a GMP network of 10 GMP facilities, part of the Andalusian Healthcare System, and have been involved in their construction and in obtaining and renewing the GMP certificate for them. Right now, 7 out of the 10 are certified to produce Advanced Therapy Medicinal Products (ATMPs). She has experience in different positions regarding Quality assurance for biotechnological products and since 2010 has also been the Qualified Person of one GMP facility, located in Seville, in which different cell therapy and tissue engineered products are authorized.
As Head of Quality Assessment she has been involved many different ATMPs clinical trials.
She has more than 15 years of expertise in training people and coordinates an international Master in Manufacturing of Advanced Therapy Medicinal Products. She has been involved in many national and international specialized congresses in the biotechnological sector and ATMPs. 
She is a Pharmacist Graduate and has a Master in Pharmaceutical Industry.  
Stephan O. Krause
Stephan O. Krause
Head of Product Quality Group at AstraZeneca Biologics, USA
Biography: Stephan Krause, PhD, is currently Quality Director and PQL Team Leader in Development Quality, AstraZeneca Biologics. He is a results-driven leader with 20 years of technical, managerial, and executive experiences for quality and technical functions within global operations. He is a frequent conference presenter and author and has won multiple industry awards for his publications and leadership in improving industry best practices. Stephan was invited by FDA several times to present an industry perspective to the agency on relevant current topics. He is a member of PDA’s Board of Directors and is co-chair of AMTP Advisory Board and a member of the Advisory Board for Biopharmaceuticals and Regulatory Affairs/Quality.
Mayra Liz Guzman-Kaslow
President & CEO at GK Pharmaceuticals CMO
Florida, United States
Biography: Mayra Liz Guzman-Kaslow is the Chairman and General Manager of GK Pharmaceuticals Contract Manufacturing Operations "GK CMO PR", sister company of GK Regulatory Compliance Corporation in Jacksonville FL-USA.

"GK-CMO PR" is the first and only Pharmaceutical and Biotechnology company in Puerto Rico that have the technology and capacity to perform Contract Development and Manufacturing Operations for Biosimilars, Biologics, Drug Substances, and Solid Drug products at the same facilities.
Also, Mayra is President & CEO / Principal Partner of GK Regulatory Compliance Corporation USA who is responsible to support all the technical projects, operations and manages our Jacksonville, FL office, and project portfolio.

Mayra hold a Master of Science in, Thermodynamics and Materials Sciences Engineering from the University of Cincinnati, OH, and 2 Bachelor in Science, (1st) in Analytical Chemistry, and (2nd) in Chemical Engineering from the University of Puerto Rico -- Mayaguez Campus. With over 26 years of experience and in-depth knowledge of FDA, EMA, MHRA, WHOs, ANVISA, COFEPRIS, ANMAT, CFDA KFDA, TGA, INVIMA, PMDA, SFDA, KFDA, ISO9001, ISO13485, Canadian, ICH Guidance, and regulations.

Track record for consistently meeting goals and delivering a high level sustained performance, proven the ability to build strong customer/client relationships to include conducting vendor audits and contract manufacturing oversight.
Mahendra Singh
Founder & CEO | Chief R&D & AI Health Innovation Officer| Chief Digital Health Officer & Chief Strategy Officer @Global DigiAIHealth | Expert Member for Digital Health, AI Health, WHO Geneva.
Biography: Mahendra is a visionary, revolutionary serial DigitalHealthTechpreneur, Passionate Next Generation Deep Tech Start-up Guru in Digital Health, AI Health &Telemedicine Innovation & Research with an exceptional synergy of Digital HealthTech Business Management Leadership+ Doctor+Engineer +Innovator &Research Scientist.

He is an Expert Member for Digital Health & Innovation, WHO Geneva.

He is working with WHO Partner 30 countries including India in Digital Health AI Health & Telemedicine Innovation.
He is World's Top 30 Most Impactful Digital HealthTech, AI Health Innovation Global Business Leader, Think-Tank, Speaker& Influencer, KOL, Voice of Healthcare & National-International Policymaker for various countries in deep Digital Health, AI Health, Telemedicine, MedTechIoT,Big Data, Blockchain &MedTech with strong 27 Yrs exp as a Most Impactful Global Business Leader.

A Digital Health & AI Health, Telemedicine Innovation Start-up management Guru.

He can predict with scientific evidence basis which Doctor& Hospital are how much Healthy or Not globally to deliver better treatment outcome & Quality Health delivery to Patient or not.

A serial Digital HealthStartup Founder &CEO, MD, COO, SVP, Director, Board Member &Advisory Board Member.

In his 27 Years exp he founded, setup, worked, built as successful serial DigitalHealthPreneur more than 9 out of his 16 Global Digital Health start-ups from Israel, India, US, UK, Germany & China from scratch Concept to Commercialization converted to Multi-Million$ MNC in an Impossible ecosystem from India to Global.

He launched 90 Innovative Nextgen Digital Health Technologies with 200 Products &Solns in next Gen innovative Healthtech driven by cutting-edge Digital Health,AI Health,Telemedicine & MedTech created tractions of 500 Million Patients globally.
60+ Clinical Trials,400+ Treatment procedures in Top10 medical super specialities including NCD. Transforming Healthcare accessible, affordable to all through disruption & Digital Health AI Health & Telemedicine Innovation for Quality Health Delivery Treatment outcome.

A game-changer, developed novel solution to solve a complex problem in Prevention, early detection, complete disease control &management in Covid19, Top20 Cancer, COPD, Diabetes, Heart & Mental Health.

Created huge value-based business on the basis of his own entrepreneur management skills.

He never give up, alway go ahead with strong will power, determination& Passion to achieve Goal.

He THINK OUT OF BOX with unique Profitable Business management with double-digit sustainable growth approach.
Ted Barduson
Ted Barduson
COO, Co-Founder at MedVector Clinical Trials
Biography: Commercially minded, and accomplished executive with extensive management experience leading all aspects of company success in the development of profit-generating strategies within start-up, turnaround, and industry-leading healthcare companies. Experience in identifying funding sources, merger and acquisition opportunities, and revenue-generating business strategies.
His professional success is due to being a responsive, approachable leader that creates opportunities for my team.
Extensive industry relationships with C-Suite executives and decision-makers at the health system and vendor partner levels. Ability to drive vision into strategic ideas, via close coordination with the management team, stakeholders, and C-level executives.

Some of his career achievements include:
● President and General Manager leading successful private equity exit via a transformation change to recurring software revenue service model, delivering yearly revenue growth of 7%, driving 11% profits, 68% gross margin, and a 166% increase in EBIDTA.
● President of La Jolla Wellness Studio and the patented MyoMetrix Method driving partnership with VEBA Health Plan of 200,000 members of teachers, police, and fire employees in southern California.
● Led sales and support driving commercial company growth from $10M revenue with 450 employees to $130M revenue with 3,000 employees, decreasing sales cycle from 11 months to 88 days, and increasing average customer size from $140,000/year to $525,000/year.

Specialties: Visionary, Strategy, Execution,Turnaround, Change,Cost Analysis,Reduction, and Control;Sales and Marketing Team Building;Customer/Company Profitability;Deal Structuring and Negotiating Skills;Growth Management and Business Development;Product Development and Rollout;Strategic/Tactical Partnership, Development;Investor, Analyst & Board Relations,Strategic Planning & Execution,Operations Management, P&L Administration, Revenue & Profit Growth,Budget & Cost Control,Private Equity,Nationally recognized public speaker,Change Management,Leadership & Team Building, Market Positioning.
Michael Sassano
Michael Sassano
Founder, Chairman & CEO Somai Pharmaceuticals; Leading Mergers as Founder of Solaris Farms; Investor, Cannabis, GMP Specialist, Alternative Medicine
Biography: Although Michael Sassano’s exciting career has led him to be involved in the fast-paced worlds of international real estate development, high-level banking, and cutting edge tech-investing, it is the cannabis space where he has shined the brightest. Michael is well known as one of the original movers and shakers in this sector, celebrated prominently in both mainstream business and cannabis media as an authority on large-scale cannabis cultivation, a pioneer of technology that affects entire markets, and an internationally respected expert on predicting long term industry trends. You can read about his advice's and progress here: https://www.somaipharma.eu/news
In July 2020, Michael led a merger of the cannabis cultivation company he built, Solaris Farms, with The Sanctuary, a local Las Vegas brand operating two dispensaries and an extraction facility. In four years with it's beginnings in private equity, Michael was able to build Solaris out from a bare lot of land into one of the largest and most well respected cannabis cultivation operations in the state of Nevada, and then further merged it into one of the top ten vertically integrated cannabis companies in the state. Michael remains on the advisory board and will help sell the new vertical to a larger company in the future.

Michael has otherwise shifted focus to his role as CEO and Chairman of the Board for Somai Pharmaceuticals LTD, an Ireland-based company that focuses on the cultivation and extraction of cannabis, and producing EU-GMP certified cannabinoid formulations for pharmaceutical distribution. Taking with him the superior cultivation and product development knowledge learned while operating a successful company in the hyper competitive western U.S. market, Somai will be one of the first American-run companies operating across legal European markets.

Michael is currently building scalable high out-put cultivation and extraction facilities in various strategic countries in Europe. The idea is to carefully develop processes for scalability and get proper registrations in order to expand as new countries legalize medical cannabis and new markets and demographics become available. The flexibility of his methods are intended to help mitigate any potential issues of government adoption by opening up avenues for adaptation and expansion as the EU market develops. As the continent ultimately comes fully online, Somai will be positioned as a top global pharmaceutical distributor of medical-grade, EU-GMP-certified cannabis.
Richard B.M. Schasfoort
Richard B.M. Schasfoort
Founder of IBIS Technologies BV
Biography: Richard B.M. Schasfoort (1959) graduated in 1984 as a biotechnology major from the University of Groningen. He defended his PhD thesis for a new approach to biosensor operation in 1989. He is founder of the company IBIS Technologies BV after selling his shares of Bio-intermediair BV in 1996. He developed at IBIS Technologies the Surface Plasmon Resonance imaging (SPRi) platform. In 2002, Richard started the Biochip group at the University of Twente after receiving the VIDI grant from NWO. He is co-author of > 100 peer reviewed papers and editor of the two Handbooks of Surface Plasmon Resonance (2008 and 2017). In the chair Medical Cell BioPhysics of Prof. Leon Terstappen, he investigates single cell binding and secretion fingerprinting of cancer cells. Since the Corona outbreak in March 2020, he changed his focus to antibody profiling using SPRi of patients with COVID19 and cooperates with the hospital Medical Spectrum Twente/Medlon.
Robert Conradt
Robert Conradt
A new Reproduction Index Ri and its relevance for an early warning system preceding a pandemic wave
Biography: I am the owner of a small company for measurement technology. Beside developments to high precision measuring devices (mainly torque, angle, force, flow rates etc.) we also develop very complex devices (e.g. ID card reader, for the biggest passport manufacturer in the world with 80% of all passports. I must admit: my favorite project). A special part of our work - and this is the origin of the paper - consists of non-university research (without public funding!). The mentioned paper is very much about good evaluation of measurement data (Covid19-data published by Robert-Koch-Institute (RKI)/ Germany). Weaknesses in the evaluation system of the RKI were found. With the correct evaluation and clever application and display of the data, one suddenly obtains insights that one (unfortunately) did not have before. This could have saved many lives and (at least in Germany) could have reduced the economic damage. Since RKI is a German federal authority, the resonance of our paper is understandably smaller in Germany than outside.
Gail Trauco
Gail Trauco
Advisory Committee Member COVID-19 FDA, Principal CEO The PharmaKon LLC, USA
Biography: The PharmaKon LLC specializes in clinical pharmaceutical product development and trials. It is a 100% woman owned business led by its CEO/founder Gail Trauco, R.N., BSN-OCN. The PharmaKon partners with biopharmaceutical and biotech companies, investigators, site staff, lab and technology vendors, and regulatory authorities to reinforce patient safety and access throughout every phase of research. All play a part in delivering the quality data that can drive promising compounds forward.
For nearly 30 years, The PharmaKon’s dedicated government and public health services group has successfully delivered clinical research services to various agencies, contractors and nonprofits in both prime contractor and subcontractor capacities within full compliance of all federal contracting requirements. Its services have supported the organizations in conducting therapeutic, vaccine and medical device studies on a global scale across all trial phases and therapeutic areas.

The PharmaKon has a unique understanding and connection to rural healthcare and underserved communities by way of Trauco’s personal experiences growing up on a family farm in her native North Carolina. Despite challenges with generational grief and poverty, Trauco persevered through high school and college at University of North Carolina at Chapel Hill and then began a life and career of her own as an oncology nurse. Trauco worked for the Chief of Surgical Oncology at Duke University Cancer Cener, Dr. Hilliard Siegler, a pioneer in the field of immunotherapy in 1957, whom she credits for her foundation of knowledge about medicine.

A registered Oncology nurse, pharmaceutical trials expert, and long-time Patient advocate, Trauco has spent four decades helping patients navigate the sea of red tape in the American healthcare system. Based just outside Atlanta, she has gained a reputation as a fierce advocate for patient’s rights and for resolving some of the most difficult medical cases in the currently crippled healthcare industry. As a lifelong healthcare professional and frequent on camera expert, Gail Trauco is equal parts Gloria Allred, Erin Brokovich, and Nancy Grace…with a small twist of Dog the Bounty Hunter.

For more information about Gail Trauco and The PharmaKonLLC visit:
https://thepharmakonllc.com/
Ahmed A Bashir
Ahmed A Bashir
GCSRT, Harvard Medical School, USA
Biography: Ahmed A Bashir is a Consultant Pediatrician, neonatologist, and Geneticist/Genomic/Molecular Genetics Researcher , I am a very motivated geneticist, Pediatrician, Neonatologist who likes to learn and teach what I learned to others. I’m passionate about what I do, and I love to help people. Nothing is more fulfilling than being part of a team with similar interests, and an organization that values its employees.
In 2007, 2010, 2013 and 2016 the hospital was again awarded the Joint Commission Gold Seal. During the past 15 years with responsibility for acute general pediatrics patients, Neonatology and Molecular genetics and Genomics, extended to Department of Pediatrics Head at Al Mana General Hospital-Jubail. Head of Al Mana Research Project since September 2016.Postdoctral Fellow in Professor Stanley Nelson Laboratory at UCLA, California, USA since June 2017.Main Research Project: Ultra rare Degenerative Diseases in Saudi Children, sponsored by King Abdulla Medical Research Center, Al Mana Group in Saudi Arabia and University of California at Los Angeles, USA.

I have Affiliations with the following Institutions: University of Khartoum, Sudan; Cairo University in Egypt; The Royal College of Surgeons, Ireland; Tulane University in New Orleans, Louisiana, USA;UCLA,LA CA,USA,; Harvard Medical School, Boston, MA,USA
Gustavo G. Cortina Rodríguez
Gustavo G. Cortina Rodríguez
Director of Quality of Life Office University of Puerto Rico- Mayaguez Campus
Biography: Gustavo G. Cortina Rodríguez is a prevention specialist and researcher in public health. He completed a bachelor's in psychology, a Master’s in Communication and Health, and a Ph.D. in Public Health with a focus on global health, risk behaviors, and public policy. He is a fellow of the Royal Society for Public Health. He has been a spokesperson on public health issues such as abuse of alcohol and other drugs, suicide, health disparities, social justice, and civil rights.
He is currently the Director of the Quality-of-Life Office at UPRM, Title IX Coordinator, and collaborates as a professor in the Psychology Department at the University of Puerto Rico in Mayagüez. He is the president and founder of Humanization in Health. He carries out an education crusade on the topics of anxiety and mental health, suicide, accessibility to health services, bullying, sexual violence, compassion, among others.
Gerard Charles
Gerard Charles
PhD Gerontology (Candidate), Singapore University of Social Sciences & Singapore General Hospital, Department of Emergency Medicine, Singapore
Biography: Gerard Charles is employed in Singapore General Hospital at the Department of Emergency Medicine. I am also currently a doctoral student in Gerontology, PhD Gerontology candidate at Singapore University of Social Sciences. My research interests lie in the fields of ageing, healthcare, nursing and gerontology.
Irina Zyrianova
Irina Zyrianova
Institute for Innovative Biotechnologies in Animal Husbandry, the branch of L.K. Ernst Federal Science Center for Animal Husbandry, Russia
Biography: Since joining the Institute for Innovative Biotechnologies in Animal Husbandry, Irina has been involved with studies of polymorphisms and phylogeny of genes and proteins of Deltaretroviruses and Betacoronoviruses. Before, Irina worked at the different Russian Research Institutions and participated in Postdoc programs at Reading (England) and Miami (USA) programs.
Huma Qamar
Huma Qamar
Senior Vice President, Head of R&D Program, FSD Pharma, Inc. USA
Biography: Huma Qamar is a Health care professional with more than 16 years of work experience in clinical medicine, surgery, pharmaceutical, Health Law, Oncology Research, patient centered outcomes research, Phase 1 trials, Women's Health, Sarcoma, Melanoma, Hematology, CART-19,Clinical Operations, Medicare Coverage Analysis, Prospective Reimbursement Analysis, Medical Affairs, Vendor Management, Good Clinical Practice (GCP), ICH, Fetal and Pediatric research, IND/IDE, Project planning, CRO, Medical Devices, Clinical Protocols, Flexible Schedule, Calibration,health outcomes research, public health, clinical research, regulatory affairs in research development, organizational delivery, Pharmacovigilance, mental health counseling, research project management, program planning and evaluation, clinical trial budgets and contracts, billing and compliance, epidemiology, electronic data capture (EDC), statistics, health marketing, information technology and business development in multiple therapeutic areas.Excellent leadership, management, interpersonal, presentation and communication skills. High degree of emotional intelligence with ability to connect with people and build strong cross-functional relationships, internally and externally.
Hetal Shah
Dr. Hetal Shah
Pharmaceuticals & CROs - Independent Consultant & Founder-Director - MeWriT Healthcare Consulting, India
Biography: Dr Hetal Shah, an expert medical writing professional by passion and profession; is currently the Founder - Director of MeWriT Healthcare Consulting.

Dr Shah is a PhD Pharmacologist with over 17 years of first-hand experience in the field of medical writing and clinical research project management. A gold medallist for her manifold academic achievements, she also has several national and international publications to her credit including book chapters, research papers and reviews.
An independent consultant with high standards for quality and work ethics, Dr Shah is extensively involved in developing integral regulatory documentation & publications for pharmaceuticals & research organizations.

As a medical writing expert, she takes full accountability for first-hand writing, editing and finalizing of submission-ready documents for various therapeutic areas. Her writing sphere currently ranges from preparation of clinical trial documents to clinical study reports; compilation of drug authorization dossiers to scientific publications for journals.

She is also an experienced trainer with practical approach to coaching, and independently conducts medical writing workshops customized for various topics and audiences’ needs. She is a member of the executive committee of All India Medical Writers Society (Under formation), member of Indian Society od Clinical Research, and an ex-member of the DIA Medical Writing group of India and ISMPP.

An accomplished professional herself, she effectively collaborates with medical experts, bio-statisticians, in-house and allied teams to ensure a complete, accurate, cost-effective, and timely solution for your medical writing needs, with the best of quality and ethics.
Dr Lia Hunter
Dr Lia Hunter
Director Clinnovate Ltd, South Croydon, England, United Kingdom
Biography: Dr Lia Hunter has over 25 years experience in the Pharmaceutical/ Biopharmaceutical Industry. She has held various positions including Research Chemist, Lecturer, Clinical Trial Administrator, Clinical Research Associate, Clinical Trial Auditor, Clinical Project Manager and Consultant. This expansive experience has developed skills and expertise such that she has overseen the progression of projects from the preclinical phase right through to market authorisation.
In 2015, Lia set up Clinnovate Ltd, a Clinical Research Consultancy, providing expertise to pharmaceutical and biopharmaceutical companies to facilitate clinical project delivery. In this capacity, Lia has successfully delivered trials within the timelines and to budget, whilst ensuring patient safety, data integrity and regulatory compliance is never compromised.

Lia has extensive experience leading key studies on high profile programmes for leading pharmaceutical companies, especially in Oncology, Gastroenterology and Infectious disease. Lia worked on a key programme for her client Takeda Pharmaceuticals in a Global position with oversight of the CRO Strategic Partner and associated Vendors and is Leading Clinical Operations Oversight at Biogen currently.
Galyna Malygina
Galyna Malygina
Senior Project Manager, LLC OtiPharm® Data Pro
Biography: An expert in the implementation and development of projects of various levels. In the IT industry since 2008, has extensive experience in other industries. Speaker of pharmaceutical forums, provide consultation to pharmaceutical companies in choosing IT products for automatisation business processes inside of the company.
Rebecca Centko
Rebecca Centko
Director of Project Management & Account Management, Regis Technologies, USA
Biography: Rebecca Centko is an Excellent communicator with a strong ability to manage business needs while delivering for clients. I have an ability to influence at all levels of the organization. I have a demonstrated history of leading a project management group with a strong understanding of the sales process, business needs, the drug development process, quality aspects, and cGMP manufacturing requirements. I can work within a team to identify and resolve problems quickly.
Mark Nuijten
Mark Nuijten
A2M, member of the MINERVA  Health Economics Network, Ltd, Netherlands
Biography: Mark is medical doctor, health economist, valuation economist, and healthcare journalist. Mark has become a leading health policy and economics expert over the last two decades, reflected in more than 200 publications and leading positions in scientific societies and editorial boards. Mark was Board Director of ISPOR (2002-2004) and Chair of the Management Board of Value in Health (2002-2004). He was member of the Editorial Advisory Board of Value in Health. He obtained his PhD in health economics (2003) on the thesis “In search for more confidence in health economic modelling” at the Erasmus University, Rotterdam.
Mark is founder of A2M (Ars Accessus Medica) and founding partner of the Minerva International Health Economic Network. Mark was trained as a physician and worked in clinical research before obtaining his international M.B.A. from Erasmus University, Rotterdam, where he later was senior staff member. Prior to setting up Ars Accessus Medica, Mark was a partner with MEDTAP International. As a VP Business Development for Europe he established global Pricing and Reimbursement Consultancy Services for MEDTAP. Before his MEDTAP period, Mark was Managing Director of the IQVIA Quintiles office in the Netherlands, which included European responsibility for the policy and health economic division.
brahim Ghareeb Madian Mohammed
Ibrahim Ghareeb Madian Mohammed
GMP executive Consultant
Biography: Quality-oriented pharmaceutical professional with 12 years’ experience in Quality assurance environment. Having sound experience in quality system improvement and in-depth knowledge in diverse GMP guidelines qualified me to be part of a global consultancy entity as GMP executive Consultant"
A. C. Matin
A. C. Matin
Professor of Microbiology & Immunology, Stanford University School of Medicine, USA
Biography: Dr. Matin has been a full professor at Stanford University for several years and is affiliated with several programs, including the Stanford Cancer Research Institute. He has contributed to many areas of biological research, including discovery of new drugs and therapeutic enzymes and their improvement as well as their specific targeting to cancer (and other diseases). He did his Ph. D. at UCLA, spent some years in the Netherlands (State University of Groningen), where he directed a research group, before joining Stanford. He is recipient of numerous awards and honors.
Ying-Xian Pan, MD/PhD
Professor Department of Anesthesiology, Rutgers New Jersey Medical School, USA
Biography: Ying-Xian Pan, MD/PhD is a Professor at the Department of Anesthesiology, Rutgers New Jersey Medical School. Core Member of Brain Health Institute, Rutgers University/Rutgers Biomedical and Health Sciences, USA.
Shreya Badhrinarayanan
Medical Director | Clinical Development
Biography: Dr. Shreya Badhrinarayanan, M.D.,  is an experienced physician with profound clinical and industry experience alongside a passion for improving patient outcomes. She has a proven track-record of providing strategic direction and leading clinical trials through collaboration with cross-functional teams. She has a thorough understanding of ICH GCP guidelines, Adverse Event Reporting, and SOPs while being well-versed in study design and execution, data analysis, and manuscript preparation. She has presented at numerous world-renowned conferences and published in high impact peer-reviewed journals. Thriving in the field of Medical Research, Leadership and Management showcased through her book and media contributions, she was nominated for the Forbes 30 under 30 Europe 2020 Healthcare Awards. During her spare time, she enjoys attending hackathons to turn ideas into reality.
Dr. Gheorghe FUNDUEANU
Dr. Gheorghe FUNDUEANU
Petru Poni” Institute of Macromolecular Chemistry-Iasi-Romania, Department of Natural Polymers, Bioactive and Biocompatible Materials, Romania.
Biography: Dr. Gheorghe FUNDUEANU is a senior researcher, Head of the Department of Natural Polymers, Bioactive and Biocompatible Materials, "Petru Poni" Institute of Macromolecular Chemistry, Romanian Academy, Iassy, Romania.

Expertise Fields: Smart polymeric materials for biomedical applications; drug delivery systems based on polymers; biomimetic hydrogels; cell culture; in vitro and in vivo testing of the polymeric biomaterials; protocols for the determination of the pharmaceuticals in biological fluids and pharmaceutical formulation.
Vuong Trieu
Vuong Trieu
Chairman & CEO at Oncotelic Therapeutics, USA
Biography: Dr. Trieu, an expert in pharmaceutical development, currently serves as CEO/Chairman of Oncotelic Inc.. Previously he was President and CEO of Igdrasol- developer of 2nd generation Abraxane- where he pioneer the regulatory pathway for approval of paclitaxel nanomedicine through a single bioequivalence trial against Abraxane. When Igdrasol merged with Sorrento Therapeutics, he became CSO and Board Director. He was Board Director of Cenomed- a company focusing on CNS drug development.
Before that he was Director of Pharmacology, Pharmacokinetics, and Biology at Abraxis where he lead the development of albumin encapsulated therapeutics along building high throughput platform for small molecules, mirRNA, kinases. Prior to that he was Group Leader at Applied Molecular Evoluton where he was developing biobetter for Humira and Enbrel. Before that he was Director of Cardiovascular Biology at Parker Hughes Institute. Dr. Trieu holds a PhD in Microbiology, BS in Microbiology and Botany. He is member of ENDO, ASCO, AACR, and many other professional organization. Dr. Trieu published widely in oncology, cardiovascular, and drug development. Dr. Trieu has over 100 patent applications and 39 issued US patents.

Submit Manuscript

Manuscript Details

Author Details